What did Cantor Fitzgerald say about ORIC on March 09, 2026?

Cantor Fitzgerald reiterated an **Overweight** rating on **March 09, 2026**, calling the recent decline an "over-reaction." The note did not include a fresh price target and emphasized confidence in ORIC’s fundamentals and pipeline.

How did Wolfe Research view ORIC on March 09, 2026?

Wolfe Research maintained a **Negative** rating on **March 09, 2026**, describing the newsflow as "mixed." Wolfe referenced an earlier roughly 12% drop and showed a **-2.18% ($-0.26)** change in its note, with no new price target.

What do these maintained ratings mean for investors?

Maintained ratings signal steady analyst conviction without new valuation anchors. Investors should treat the ORIC analyst rating split as a cue to check upcoming catalysts, trial timelines, and risk tolerance before adjusting positions.

How does Meyka AI rate ORIC and what does the grade cover?

Meyka AI rates ORIC with a grade of **B**. The grade evaluates S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are not guarantees and are not financial advice.

Analyst Ratings

March 2026 Cantor Fitzgerald Maintains Overweight on ORIC (ORIC)

ByDanny Kontos March 10, 2026March 10, 2026

Cantor Fitzgerald maintained an Overweight rating on ORIC Pharmaceuticals, Inc. (ORIC) on March 09, 2026, calling the stock’s recent drop an “over-reaction.” The ORIC analyst rating picture is mixed the same day, as Wolfe Research also maintained its Negative view. Both notes arrived March 09, 2026 and help explain intraday volatility and investor sentiment. We review each firm’s view, how the moves connect to share performance, and what the ratings mean for investors tracking ORIC analyst rating changes.